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Aim: Azelaic acid (AzA), a comedolytic, antibacterial, anti-inflammatory anti-melanogenic agent,
prescribed against acne vulgaris is safe on skin. Its combination with another widely used anti-acne
agent, tea tree oil (EO) whose delivery is limited by volatility, instability and lipophilicity constraints
was attempted. Method: Solvent injection was used to prepare AzA-EO integrated ethosomes. Result:
Ethosomes were transformed into carbopol hydrogel, which exhibited pseudo-plastic properties with
appreciable firmness, work of shear, stickiness and work of adhesion. The hydrogel showed better
permeation and retention characteristics vis-a-vis commercial formulation (AzidermTM), when evaluated
in Wistar rat skin. Further, ethosome hydrogel composite was better tolerated with no side effects.
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Acne vulgaris is a consequence of multiple etiologies such as hyper-seborrhoea, dysregulation of the hormone
microenvironment, bacterial colonization and host inflammatory response [1]. It is one of the most common
dermatological disease and is associated with various psychiatric comorbidities such as depression, anxiety, social
inhibition, body dysmorphia and social ideation, especially due to scarring and pigmentation [2]. Open or closed
comedones and pustules, papules, nodules are non-inflammatory and inflammatory manifestations of the condition,
respectively [3].
It is desirable to target hair follicles, have increased drug permeation and deposition, improved bioavailability at
selected sites in acne and similar conditions [4]. Topical therapy can provide aforementioned benefits when used in
conjunct with or as an alternative to systemic therapy. The topical agents commonly prescribed include retinoids
(tretinoin, adaplene, tazarotene, isotretinoin and metretinide), antibacterial agents (clindamycin, erythromycin,
clarithromycin, azithromycin and nadifloxacin), antiandrogens (Cyproterone acetate) [5]. These drugs are, however,
associated with numerous side effects, and some have even developed bacterial resistance over the last decades [6].
Natural AzA can be used topically to treat mild-to-moderate acne.
Azelaic acid (AzA), a dicarboxylic acid analog, is an anti-infective, anti-oxidative, anti-inflammatory, inhibits
follicular keratinization and epidermal melanogenesis. It works by inhibiting the expression of proinflammatory
cytokines, downregulating cathelicidins, inhibiting ROS production by granulocytes, thereby exerting its anti-
inflammatory activity. It reduces the stratum corneum thickness, decreases the number of keratohyalin granules,
reduces the amount, distribution of filaggrin in epidermal layers, reduces cell proliferation, is a competitive inhibitor
of important mitochondrial respiratory chain enzymes, such as NADH dehydrogenase, succinic dehydrogenase,
ubiquinone cytochrome c oxidoreductase. Through all these actions it exerts its anti-keratinizing action. By lowering
of bacterial intracellular pH by the drug, pH gradient across the cell membrane ceases to be maintained, causing the
bacteria to lose energy, leading to antibacterial activity. Melatonin generation is inhibited by inhibiting tyrosinase
like enzymes causing of melanin and melanosomes to degrade [7].
However, AzA has poor aqueous solubility (≈0.24 g/100 g of water at 25◦C), and penetrability across the skin.
Therefore, it needs to be formulated at higher dose of 10% w/w or 20% w/w to achieve the desired therapeutic
effect. This is however limited by dose-dependent side effects like erythema, burning, stinging and tingling, dryness,
scaling and peeling and warrants development of a novel strategy for its effective delivery.
Tea tree essential oil (EO) is isolated by steam distillation of follicular leaves from plant Melaleuca alternifolia.
The antioxidant, anti-inflammatory property, and broad spectrum anti-microbial activity, of EO make it useful as a
complementary drug in acne. It has been used for many years in the treatment of acne vulgaris [8,9] and successfully
combined with benzoyl peroxide, erythromycin [10], adapalene [11] previously with promising results. However, it
is limited by volatility instability, lipophilicity constraints.
Thus, to overcome the limitation of both the bioactives, they can be co-formulated for the management of acne
vulgaris. EO ethosomes have been reported as an effective treatment of atopic dermatitis [12]. There is a Korean skin
care serum of brand Cos De BAHA that uses a combination of azelaic acid (5%), EO and few other actives. The
product is popularly sold as a ‘multi-action powerhouse’ and promises to clear cystic acne. In the present research the
combination of AzA and EO has been encapsulated, to achieve targeted and safe delivery. Although EO could have
been quantified, however as no suitable analytical method was found for the same. Hence quantification of EO was
not performed. Similar research have used a combination of adaplene and EO before [11]. During the past few years,
novel nano-carriers have been reported as effective vehicles for delivering AzA to the skin, for example, via liquid
crystal systems [12], liposomes [13], ethosomes [14], proethosomes [15], nanoparticles [16], leciplex, invasomes [17],
nanostructured lipid carriers [18], nano emulsion [19] and microemulsion [20]. EO has also been formulated as
nanoemulsion [21], liposome [22], ethosome [23], microsponges [24], nanoparticles [25] and microcapsules [26]. The
ethanolic vesicle (EV) is a new type of vesicular carrier consisting of phospholipids that are arranged in one or more
overlapping bilayers surrounding numerous small pockets of aqueous solution. Biocompatibility, biodegradability
and the presence of lipid component have made ethosomes the most rationalized carriers for delivering medicine. In
addition having advantages of easy membrane transport, sustained drug release, safeguarded encapsulated bioactives,
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enhanced bioavailability, skin penetration through pores smaller than their size, easy applicability in the form of
gels and ointments, circumventing toxicity problems, possessing affinity for both hydrophilic and lipophilic drug
and easy to scale up manufacturing process makes it a unique carrier for drug delivery.
In this study, the potential for co–administration of AzA and EO was evaluated encapsulated in ethosome,
to synthesize a system with synergistic anti-acne properties within carbopol hydrogel, enhance targeted delivery
of active drugs into pilosebaceous glands so as to provide prolonged action with negligible adverse effect. Here,
we studied the rheological behavior and textural attributes of the hydrogel for its intended topical use. We also
demonstrated its antibacterial efficacy against S. aureus, S. epidermidis and P. acnes. Ex vivo skin permeation and
retention of AzA from different systems, were also tested by means of Wistar rat skin and were compared with
marketed formulation. The developed optimized ethanolic vesicles formulation of AzA and EO was compared with
topical marketed formulation in the testosterone induced acne model in Swiss Albino mice.
Materials & methods
Materials
AzA was purchased from TCI Chemicals Pvt. Ltd., Chennai, India. EO (Melaleuca alternifolia) was purchased
from Allin Exporters, Noida, India. Phospholipipon 90G (PL-90G) was supplied ex gratis by Phospholipid GmbH,
Germany. Dimethyl sulfoxide (DMSO), Carbopol 934, PEG 400, Triethanolamine (TEA), Acetonitrile (ACN),
Sodium dihydrogen orthophosphate and orthophosphoric acid were purchased from Loba Chemie Pvt. Ltd.,
Mumbai, India. Absolute ethanol was purchased from Changshu Hongsheng Fine Chemical Co. Ltd., Chagshu,
China, while sephadex G-50 was purchased from Sigma Aldrich Chemie, GmbH. Nutrient broth (NB), Agar, Brain
heart infusion (BHI), Erythromycin and Resazurin Dye were purchased from Himedia Labs Pvt. Ltd., Kolkata,
India. The commercial formulation of azelaic acid employed in the study was Aziderm R© 10%w/w gel (Micro
labs Ltd., Banglore, India) procured from local drug house. Ultrapure water prepared by Micropore ™ was used
throughout the study.
For experimentation guidelines were followed as dictated by CPCSEA (Committee for the purpose of control and
supervision of experiments on animals). Institutional Animal Ethical Committee of [ANONYMIZED] University
approved the experiments (IAEC/SU/09/18). Male Swiss Albino mice and Wistar rats used in the current study
were collected from [ANONYMIZED] University’s central animal house (H.P).
RP-HPLC instrumentation & chromatographic conditions for AzA analysis
The AzA analysis was carried out on an HPLC system (Agilent Technology 1200 series, Chandigarh, India) equipped
with double beam U.V spectrophotometer (Systroni2202, India Pvt. Ltd., Mumbai, India), pressure controlled by
prominence pump and operated by EZChrom software. Innoval C18 column (250 × 4.6 mm, particle size 5 μm)
was used for the separation. Two different mobile phase solvents for pumps were, (50:50) sodium di-hydrogen
orthophosphate (NaH2PO4; pH 3.5; 50 mM) Pump A, and ACN for pump B. Mobile phases were filtered through
a 0.45 μm nylon membrane filter and ultra-sonicated for 30 min. Samples were filtered through the nylon syringe
filter of 0.22 μm pore size, prior to the injection. Sodium di-hydrogen orthophosphate and ACN (50:50) v/v
mixture was used as mobile phase in gradient mode. The flow rate was set at 0.6 ml/min. Samples volumes were
10 μl and PDA detector was set at 321 nm. Run time of the samples was 30 min. Analysis was conducted at a
detection wavelength of 250 nm. A constant temperature of 25◦C was maintained in the column [27].
AzA & EO compatibility studies
Compatibility studies were performed for azelaic and EO using FTIR.
Preparation of AzA & EO loaded ethanolic vesicles
As shown in Table 1, a total of 8 formulations for ethanolic vesicles (EVs) were prepared with phospholipid
(PL-90G) concentrations ranging from 10 to 20% w/w. EtOH concentrations ranged from 10 to 40% w/w. All
formulations contained 5% w/w. As per the previously published studies 5% azelaic acid and 5% EO concentrations
have been used individually for treatment of acne vulgaris [28,29]. AzA and EO. Cold method is the most common
way of preparing EVs [30] according to which PL-90G, AzA and EO were dissolved in ethanol to a clear solution.
Consequently resultant alcoholic solution was poured into the aqueous phase, it was mixed at 1000 rpm. Stirring of
the alcoholic solution continued for five minutes after it had been transferred. The EVs so obtained were properly
stored until further use.
future science group 10.4155/tde-2021-0059
Research Article Bisht, Hemrajani, Upadhyay et al.
Table 1. Compatibility study of azelaic acid and tea tree oil using FTIR spectrum.




1 1700 cm-1 Dicarboxylic acid 2883 cm-1 -CH cyclic stretch 1700 cm-1 Dicarboxylic acid of AzA
2 2943 cm-1 Hydroxyl group 2965 cm-1 -CH stretch 2965 cm-1 -CH stretch of EO
3 1104 cm-1 (O-C) ether bond in
plane
1655 cm-1 -C=C cylic stretch 1104 cm-1 (O-C) ether bond of AzA
4 1201 cm-1 (O-C) ether bond out of
plane
3702 cm-1 -OH stretch 3702 cm-1 -OH stretch of EO
5 2853 cm-1 Methylene group – – – –
AzA: Azelaic acid; EO: Tea tree oil.
Characterization of AzA & EO co-loaded EVs
Vesicular size & size distribution
The Zetasizer (Malvern) was used to measure the mean size and distribution of EV. A quartz cuvette containing
distilled water was used for the size measurement, and the scattering angle was 90 degrees. A triplicate of each
observation was noted [31].
Zeta potential
Zeta potential for optimized EV formulation was determined using Zetasizer-LS13320 (Delsa™Nano C Beckman
coulter). The final result for the sample was the average of three measurements [32].
Percentage entrapment efficiency by ultra-centrifugation method
Ultracentrifugation test was conducted in triplicate to determine the percentage EE (%EE). The EV formulation
was centrifuged (REMI CPR 24) at 23,980 ×g for 2 h, at 4◦C. The drug content of the clear supernatant as well as
the vesicular sediment after methanol lysing was determined. The appropriate dilutions were made, and RP-HPLC
technique was used to analyze them. Calculation of the% EE was done using the following equation:
EE =
(T − C )
T
× 100 (Equation 1)
Where, the total amount of drug detected in both the supernatant and sediment is T, and the amount only
detected in the supernatant is C [33].
Flexibility index
By means of a vesicle-extrusion device (Eastern Sci. Inc., MD, USA), EV carriers were measured for their membrane
flexibility index (FI). In the experiment, vesicular suspensions were extruded through polycarbonate membranes
with pores of 0.05 μ sizes. Utilizing the Delsa Nano particle size analyzer (M/s Beckman Coulter Inc., CA, USA),






Where PE and PA are the values of pre and post-extrusion particle sizes, respectively [34].
Optical microscopy
Phase contrast optical microscope (RXL-5 (B-7692) equipped with a CCD camera was used to measure EV
morphology, namely, shape uniformity and lamellarity [33].
Incorporation of drug-loaded EV in the hydrogel
EV incorporated in hydrocolloids facilitates easy application, adhesion and apt drug penetration [34]. To augment
topical spreadability, ethosome was further incorporated into 10% by weight of neutralized Carbopol R© 934
hydrogel. The final percentage of Carbopol in the gel was found to be 1% w/w.
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Characterization of ethosomal gel
Organoleptic properties
In order to assess organoleptic attributes like feel, transparency, tackiness and grittiness, all of the selected EVs were
visually examined. Transparency was determined by viewing EV hydrogel against a white light source, and other
characteristics were determined by gently rubbing EV hydrogel between thumb and forefinger.
Rheology & texture analysis
The rheogram of the EV gel was constructed by using rotational rheometer (Make-Anton Par, Model-Rheolab QC).
An approximate weight of 5 g of gel was placed in sample holders with diameter 9.995 mm and length 14.987 mm.
The shear stress value was observed. The relation between shear stress (τ) and shear rate (γ) was determined by
power law and Herschel-Bulkey model (Equations 3 and 4).
τ = τo + ky n (Equation 3)
τ = ky n (Equation 4)
Where k is consistency index (Pa secn), τo is yield stress (Pa) and n is power law exponent.
The texture properties of gel was analyzed by Texture analyzer™ (TA.XT plus Texture analyzer M/s Stable
Microsystem, Surrey, UK). Sample (15–20 g) was retained into the lower cone. In order to ensure the starting point
for each test was the same height, the upper cone probe was calibrated against the lower cone beforehand. The
probe reaches a depth of 2 mm above the surface of the sample holder by approaching and then penetrating the
sample, as a result, the probe moved 23 mm from its starting point (with test speed of 3.0 mm/s.).
In vitro anti-bacterial activity
The antibacterial activity of AzA, EO, AzA-EO, EV and EV gel formulations were studied against two bacterial
strains namely Staphylococcus aureus (ATCC 29213), Staphylococcus epidermidis (MTCC 3382). Bacterial strains, S.
aureus and S. epidermidis were cultured in nutrient broth (NB) medium, and incubated at 37◦C for 24 h.
Antibacterial agar well diffusion assay
Antibacterial activity was done by using agar well diffusion method. In 100 mm sterile petridishes, approximately
25 ml of media was poured in and allowed to solidify. Using sterile coEOn swabs, bacterial culture of 0.2 McFarland
Standard 600 nm was evenly spread over the media plates. Different formulations were added into the separate
wells punched with the cork borer (6 mm) in the agar. AzA, EO and AzA-EO combination were diluted in 99.9%
ethanol so as to have test concentration as 50 mg/ml for AzA, 50 mg/ml for EO, and 50 mg/ml each for AzA-EO
combination. EV containing AzA 50 mg/ml and EO 50 mg/ml loaded directly into the wells, while EV gel was
first diluted in the DMSO, so as to have the test concentration as 50 mg/ml each for AzA and EO. After the
incubation of 24 h at 37◦C for S. aureus and S. epidermidis, zone of inhibition was determined using HiAntibiotic
Zone scale-C. The positive control for S aureus and S. epidermidis was erythromycin (1 mg/ml).
Determination of minimum inhibitory concentration
In broth microdilution assay, minimum inhibitory concentration (MIC) was determined for various bacterial
strains with AzA, EO (EO), AzA-EO, EV, and EV gel formulations. MIC is one in which no visible growth of
the organisms tested is achieved. (Poomanee et al., 2018). To determine the MIC, 100 μl of each test formulation
was taken in a flat-boEOm 96-well micro-titer plates containing 100 μl of NB for S. aureus and S. epidermidis.
Subsequently each well pertaining to every test formulation was serially diluted in ratio of 1:1 upto 12th well.
10 μl of bacterial culture suspension (1 × 108 cells/ml) was added to the each well. On each plate there were also
designated wells for controls namely medium control, and test control (AzA, EO, AzA-EO, EV and EV gel alone)
without any bacterial inoculums. Control for inoculums viability was also reserved, wherein no test formulation
was added. The plates were incubated for 24 h at 37◦C for S. aureus, and S. epidermidis. Resazurin dye (10 μl) was
added after incubation, and the color change was observed visually. As growth took place, the color of the growth
changed from purple to pink or colorless. An MIC value was calculated by finding the concentration at which color
change from purple to pink. The samples were all analyzed in triplicate [35].
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Ex vivo skin permeation studies
Studies on ex vivo skin permeation were undertaken with Wistar rats (from control groups used in in vivo skin
compliance study) using a diffusion cell with an effective diffusional area of 2 cm2. Rat skin, despite its thinness was
utilized because it was easy to procure, could be removed fresh before to the skin permeation investigation, had the
appropriate viability, enzymatic activity and is often reported to exhibit minimal variability in permeation results [36–
39]. Moreover, it is anatomically similar to human skin and is frequently employed in permeation experiments due to
its ease of availability, ease of handling, as well as low cost [40]. Although porcine skin would have been an excellent
choice (as it has greater structural similarities with human skin), it could not be used due to a lack of availability.
By dislocating spine of Wistar rat, they were sacrificed and their dorsal surface hair was removed with electric
clippers. Following that, sterile scissors were used to free the harvested skin from adhering adipose tissue. After the
tissue had been equilibrated with 0.9% normal saline for 1 h, it was mounted between the donor and receptor
compartment of the diffusion assembly having a receptor volume of 15 ml. With a magnetic stirrer, diffusion
medium (Ethanol: Phosphate buffer pH 6 (30:70)) was continuously stirred, while an air jacketed thermoregulator
maintained the assembly at 32◦C. Separate formulations (i.e. AzA-EV, AzA-EV gel and Aziderm R©) of 0.5 g were
then loaded into each assembly’s donor compartment. To maintain the sink condition, 1 ml aliquots were collected
from the sampling port and replaced with fresh solution and the sampling was done at 0.5, 1.5, 4, 6, 9, 12 and
24 h. The concentration of AzA in the receptor compartment was analyzed by validated RP-HPLC method and
the cumulative amount of AzA permeated was reckoned using Equation 5. The graph between cumulative amount
permeated (μg/cm2) versus time was also plotted [34].
Qn = CnVo + n=1i=1 Ci × Vi (Equation 5)
Cn denotes the time at which each sample of the receiver medium is analyzed for drug concentration, Ci is ith
sample drug concentration, V0 and Vi are sample and receiver solution volumes, respectively.
Skin retention studies
The skin mounted on the diffusion cell was carefully removed following the completion of the permeation studies.
An analysis of the drug content of the adhered formulation on the skin was conducted. Using ultrapure water, the
tissue was washed three-times and then dried on a lint-free coEOn swab. The cleared skin was then macerated
in methanol for 24 h and then macerated using tissue homogenizer. Further centrifugation at 7000 rpm was
performed, followed by RP-HPLC analysis to quantify the drug from the supernatant [34].
In vivo studies
Skin compliance study
Wistar rats were used for the skin compliance studies. Three group of rats consisted of three animals each. There
was an ad libitum supply of water and food for each animal in its separate cage. Clippers of 0.1 mm diameter were
used to remove hair on the dorsal side of the animals. Using a water-soaked cotton swab, the skin was swabbed
three- to four-times. The first group was not treated (control), while the second and third groups were treated with
AzA-EV gel and MKT (marketed formulation), respectively. Two weeks, after daily application of the designated
treatment or control, the formulation remaining on the skin was removed with a dry cotton swab, then cleaned
with a wet cotton swab. A digital camera was used to photograph the skin areas after 1 h of cleaning. Animals
were sacrificed, and skin samples were collected and appropriately processed before staining with haematoxylin and
eosin. The samples of processed skin were examined microscopically for histopathological changes, if any [32].
Anti acne activity: testosterone-induced acne model
A total of four groups of Swiss Albino mice (male) weighing 20–30 g had three animals in each group. To induce
the acne, testosterone (TS) solution (2% ethanolic) was painted to groups 2 to 4 dorsally whereas group 1 acted as
control group. Two weeks after acne was induced, AzA formulations (0.1 g per 4 cm2) were applied once-a-day for
2 weeks continuous. As a control group, group 1 received only normal saline whereas for group 2, no treatment was
administered (disease control), while for groups 3 and 4, AzA-EV gel was applied and MKT was used, respectively.
There was a careful check for papules or other noticeable changes in the skin. Following treatment, the anti-acne
effects of various formulations were determined by measuring decrease in papule density per 4 cm2 area. The
sacrificed animals’ skin was harvested after the study concluded. Transverse sections of each specimen were made
after fixing it in 10% formalin and embedding it in paraffin. Skin samples were processed and stained with
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Figure 1. Drug excipients compatibility study. FTIR spectrum of (A) azelaic acid, (B) tea tree oil and (C) azelaic acid and tea tree oil.
haematoxylin and eosin appropriately. Observations were made microscopically for changes in number and size of
sebaceous glands in the processed skin samples [41].
Stability studies
One month stability studies were performed for ethosome formulation and hydrogel. Optimized formulations were
stored at 4 ± 2◦C, 8 ± 2◦C and room temperature. Percent drug entrapment was determined at different time
intervals (1, 7, 15, 30 days) and noted.
Results & discussions
AzA & EO compatibility studies
In the FTIR of AzA and EO (Figure 1) characteristic bands of AzA and EO were visible (Table 1), indicating no
interaction and presence of compatibility between the two compounds (AzA and EO).
Formulation selection & characterization of the EV systems
The various characterization parameters of prepared drug loaded EVs are depicted in Table 2. It was observed that%
EE of AzA in EV formulations was high, this could be ascribed to high lipid amount, and solubility of AzA in
ethanol, which enabled entrapment of the drug inside vesicles. Varying the PL-90G and ethanol concentration did
not influence the% EE appreciably. It is primarily the size of the vesicles that determines the overall effectiveness
of a topical drug delivery system. The DLS studies showed that the vesicular size, of the different EV systems, was
in nano-metric size range between 312.3 and 789.4 nm. On increasing the concentration of PL from 10 to 20%
w/w and ethanol 10 to 30% w/w the vesicle size varied noticeably. At constant PL-90G concentration, in other
words, 10%, as ethanol concentration was augmented to 30%, the size of the vesicle augmented considerably. This
may be due to high ethanol concentration in the bilayers of the vesicles, which may have reduced the rigidity, and
increased the elasticity of the lamellar structure and thus resulted in increased vesicle size. However at 15% PL
concentrations, it was noted that increase in ethanol content up to 20% w/w resulted in the decrease in vesicle
size, followed by an increase. At higher ethanol concentrations, vesicle size decreases due to the solubilization of
phospholipid bilayers. Out of a total of eight combinations, formulations EVO-1, EVO-7 and EVO-8 resulted in
formation of clear solution and unstable system, and were devoid of any microscopically visible vesicles. Hence, the
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Table 2. Composition of azelaic acid-tea tree oil-loaded ethanolic vesicle formulations, particle size, polydispersity index
and percentage entrapment efficiency of selected ethanolic vesicle formulations.
Sample ID AzA (mg) EO (mg) PL-90G (g) Ethanol (g) Water (g) Particle
size (nm)
PDI %EE
EVO-1 500 500 1 1 7 – – –
EVO-2 500 500 1 2 6 399.3 0.821 99.95
EVO-3 500 500 1 3 5 789.4 0.147 99.91
EVO-4 500 500 1.5 3 4.5 447.9 0.595 99.93
EVO-5 500 500 1.5 2 5.5 312.3 0.396 99.86
EVO-6 500 500 1.5 1 6.5 474.5 0.678 99.88
EVO-7 500 500 2 3 4 – – –
EVO-8 500 500 1.5 4 3.5 – – –




Figure 2. Microscopic evaluation of azelaic acid–ethanolic vesicle formulations. (A) Microphotograph of different
azelaic acid entrapped ethanolic vesicle formulations at 100× employing optical microscope (B) TEM image of
optimized marketed (Melaleuca alternifolia) formulation (magnification 200,000×).
concentration ranges of PL and ethanol were selected as 10–15% and 10–30%, respectively, for further studies. The
optical microphotographs of different EV formulation are illustrated in Figure 2. All formulations had sphere-like
vesicles. The appreciable population of vesicles were without any aggregation or agglomeration, lamellar character
of the vesicles could also be visualised. EVO2 and EVO5 exhibited desired size <400 nm and were tested for
antibacterial activity, which was found to be 24.6 ± 0.5 mm (EVO2) and 18 ± 1 mm (EVO5). Thus EVO2 was
selected for further evaluation as it showed greater zone of inhibition. All the subsequent evaluations were carried
out employing this composition of EV. The final EVO2 formulation contained 10% PL and 20% ethanol w/w, with
minimum particle size 399.3 nm, polydispersity index = 0.821. Further, the size distribution of AzA-EO co-loaded
EVs (Table 2) measured using DLS displayed one narrow peak (Figure 3A), suggesting a relatively homogenous
vesicle population. Zeta potential of selected EV dispersion was observed as +1.62 mV (Figure 3B). Even though
electrical charge on nanoparticles has insignificant impact on their target potential [42], the positive value of the zeta
potential may contribute to the ethosomal system’s ability to permeate skin due to its attraction with negatively
charged surfaces [43]. Phospholipid 90 G or AzA may have contributed to positive zetapotential value. Low positive
zeta-potential values [44] and high positive zeta potential values [45] have been previously reported for ethosomes.
The TEM microscopic image (magnification 200,000×) revealed no aggregation. The vesicles were unilamellar,
spherical, and nanometric in size, as illustrated in Figure 2B. In order to assess the membrane flexibility of the
EVs, the FI was determined using a vesicle extruder (Easter Sci. Inc., MD, USA). This is a critical and specific
parameter which enables EVs to be distinguished from conventional vesicular carriers, like liposomes, on the basis
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Figure 3. Characterization of optimized azelaic acid–ethanolic vesicles. (A) Particle size distribution of azelaic acid-loaded ethanolic
vesicle (B) Zeta potential of optimized azelaic acid–ethanolic vesicle dispersion.
Figure 4. Photomicrograph showing the images of azelaic acid and tea tree oil-loaded ethanolic vesicles and
ethanolic vesicle gel formulation.
of flexibility and ability to cross the stratum corneum. EVs displayed a FI value of 3.28. This can be explained by
the presence of ethanol in the bilayers of ethosomes, which increases their softness and malleability.
Characterization of AzA & EO-loaded EV hydrogels
The AzA-loaded EVs were found to be turbid and white in color (Figure 4). No signs of any kind of phase separation
and creaming was observed. The optimized EV hydrogel exhibited smooth feel with no grittiness and tackiness.
Rheological and texture characteristics of optimized AzA-EV gel are shown in Table 3. The rheological profile
of the hydrogel, showed moderate viscosity and pseudoplastic behavior, also confirmed by n value less than 1
(Figure 5A). The viscous hydrogel is composed of long-chain polymer molecules that are hooked and entangled at
a static or low flow rate. When the shear rate increases, the dispersed polymeric chains are rolled and contracted
into a group and hence decrease the apparent viscosity, which leads to the phenomenon of shear thinning [46].
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Table 3. Rheological and texture characteristics of azelaic acid and tea tree oil-loaded ethanolic vesicle gel.
Formulation parameter AzA-EV gel
N 0.332
k (Pa) 17.85
Yield value (Pa) 54.54
Viscosity (Pa-s) 3.43
Firmness (g) 45.572
Work of shear (g-s) 32.483
Stickiness (g) -37.937
Work of adhesion (g-s) -13.793
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Figure 5. Physical characterization of azelaic acid–ethanolic vesicle gel. (A) For optimal azelaic acid–ethanolic vesicle gel, plots of shear
rate versus viscosity and shear rate versus shear stress is shown. (B) Presents textural analysis of azelaic acid–ethanolic vesicle gel.
The resulting force-time curve (Figure 5B), textural parameters of cohesiveness (amount of work done during
the second compression divided by amount of work done during the first compression), adhesiveness (g∗s; negative
area of cycle 1 representing work undertaken to remove the compressing probe from the sample), spreadability
(work of shear), forward extrusion (firmness), stickiness (area of the negative force curve), were noted.
Gel yield value was moderate (54.54 Pa) which indicates adequate rigidity of the system. Other parameters
obtained were good firmness (45.572 g), work of shear (32.483 g-s), work of adhesion (-13.793g-s), and stickiness
(-37.937 g). The developed EV hydrogel composite the cohesiveness was adequate, which is necessary to retain
the formulation at the application site. These factors predicted the hydrogel’s appreciable mechanical strength, easy
application, and capability to easily extrude from tubes, characteristics that are essential for its topical application.
In vitro antibacterial activity
Investigation of antibacterial activity of AzA, EO, AzA & EO, EV & EV gel formulations
Table 4 and Figure 6 elucidate diameters of bacterial zones inhibited by multiple test formulations. Ethanol and
DMSO, taken as negative control did not show any activity whereas erythromycin employed as +ve control
demonstrated excellent antimicrobial activity against the test microorganism. The antibacterial property of AzA
was also demonstrated against S. aureus and S. epidermidis. Surprisingly EO alone did not exhibit any activity
against both the test organisms, this could be due to the fact that EO is not affective at such low concentration
(50 μg/ml). However in combination with AzA revealed appreciable activity, it may be because the cells become
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Table 4. Diameters of bacterial inhibition zones observed using azelaic acid, tea tree oil, azelaic acid and tea tree oil,
ethanolic vesicle and ethanolic vesicle gel formulations.
Formulations Concentration Volume used Diameter of inhibition zone,  ± S.D. (mm); amount of
antibacterial tested (mg/ml)
ATCC 29213 (S. aureus) MTCC 3382 (S. epidermidis)
AzA 50 mg/Ml 80 μl 21.3 ± 0.5 20.6 ± 1.1
EO 50 mg/Ml 80 μl N D N D
AzA with EO 50 mg/ml + 50 mg/ml 80 μl 15.3 ± 1.5 16 ± 1
EVO-2 50 mg/ml 80 μl 21.3 ± 1.1 22.3 ± 0.5
EVO-2 gel 50 mg/ml 80 μl 24.6 ± 0.5 23.6 ± 1.5
Erythromycin (+ve) 1 mg/ml 10 μl 23 ± 1.0 29 ± 1.0
Ethanol (-ve) – 80 μl ND ND
DMSO (-ve) – 80 μl ND ND
AzA: Azelaic acid; EO: Tea tree oil; ND: No zone of inhibition detected; the zone of inhibition values are an average from two independent experiments.
Figure 6. Antimicrobial activity of azelaic acid, tea tree oil, ethanolic vesicle and ethanolic vesicle gel formulations
against S. aureus and S. epidermidis. (A) (SA) AA 50 mg/ml in ethanol, EO 50 mg/ml in ethanol,
A + E 50 mg/ml + 50 mg/ml, ethanol (-ve) and +ve 1 mg/ml. (B) SA EV – 50 mg/ml, EG – 50 mg/ml in DMSO (-ve) and
+ve (1 mg/ml). (C) SE AA 50 mg/ml in ethanol, EO 50 mg/ml in ethanol, A + E 50 mg/ml + 50 mg/ml in ethanol,
ethanol (-ve) and +ve (1 mg/ml). (D) SE EV 50 mg/ml, EG 50 mg/ml in DMSO (-ve) and +ve (1 mg/ml).
+ve: Erythromycin; AA: Azelaic acid; A = E: azelaic acid + essential oil; EG: Ethanolic vesicle gel; EO: Essential oil; EV;
Ethanolic vesicle; SA: S. aureus: SE: S. epidermidis.
more susceptible to the bactericidal effects of EO, owing to the keratolytic effect of AzA. On one hand, while the
activity of AzA and EO loaded EV was comparable to AzA against S. aureus. It was significantly better in case
of S. epidermidis. Further AzA and EO loaded EV gel demonstrated vis-a-vis all the formulations highest zone of
inhibition (≈23 ± 1.0 mm) against both the tested organisms. The antibacterial effects of AzA have been well
documented, making AzA a useful material in the treatment of acne and inflammatory skin diseases [47]. In all the
microorganisms tested, EV exhibited antibacterial activity by interacting with the microbial cellular membrane or
cell wall [48].
Minimum inhibitory concentration of AzA, EO, AzA & EO combination, EV & EV gel formulations against different
bacterial strains
The order of minimum inhibitory concentration (MIC) values (Table 4) against S. aureus was observed to be as
follows: EO ≈ EV hydrogel (3.12 mg/ml)> AzA ≈ AzA with EO (0.76 mg/ml) >EV (0.09 mg/ml) >Erythromycin
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Figure 7. Skin permeation and retention studies of azelaic acid–ethanolic vesicle gel. (A) A comparative
representation of ex vivo skin permeation profiles of AzA from EVs, EV gels and MKT. (B) Plot showing the skin
retention values of EV, EV gel and MKT.
AzA: Azelaic acid; EV: Ethanolic vesicle; MKT: Marketed formulation.
(0.02 mg/ml). For S. epidermidis MIC values were found to be as follows: EO (6.25 mg/ml) >EV hydrogel
(1.56 mg/ml) >AzA≈AzA with EO ≈ EV (0.78 mg/ml) >Erythromycin (0.02 mg/ml). However, EO alone does
not have a significant antibacterial effect, but AzA loaded EO EV demonstrated significantly lower MICs when
compared with EO alone. It is believed that the superior efficacy of EV hydrogel may be attributed to the synergistic
effects of the AzA and EO, as well as improved contact with the bacterial cell wall, resulting in an increased contact
time and sustained delivery [11].
Ex vivo skin permeation studies
The cumulative amount of AzA, permeated and penetrated (conveyed as cumulative amount permeated (μg/cm2))
after 24 h, is depicted in Figure 7A. It observed the following order: EV (186 μg/cm2) >EV hydrogel
(135.13 μg/cm2) >Aziderm R© (102.49 μg/cm2). Ethanol due to its penetration enhancement effect imparts
flexibility to EV and hence is responsible for maximum penetration observed in the studies. EVs exert pull and
push effects on the intercellular interface of the stratum corneum cells and enhance drug penetration [49]. Push
effect is a thermodynamic effect of ethanol evaporation, and pull effect is a result of ethanol fluidizing SC lipids.
Additionally in preparation of the EV formulations, the PL-90G and ethanol interact synergistically to increase
penetration. However, addition of Carbopol 934 into EV (AzA-EV gel) decreases the permeability of AzA. This
could be due to the higher viscosity of hydrogel than that of EV, hindering mobility and preventing permeation of
drugs [50].
Ex vivo skin retention studies
Figure 7B illustrates how much AzA was retained in the skin with different formulations. The skin retention
observed the following order: EV hydrogel (22.51 μg/cm2) >Aziderm R© (19.64 μg/cm2) >EV (16.25 μg/cm2).
In comparison to marketed formulations, higher retention can be attributed to the ability of EV hydrogel to create a
reservoir within skin layers more efficiently and also to more close contact between the drug and skin lipids thereby
increasing drug retention.
In vivo skin compliance study
The images in Figure 8 show skin surface of a Wistar rat exposed to normal saline (Control), EV gel, and MKT
gel. Compared with the control-treated group (Figure 8A), the EV-treated group showed little change in the
skin histology, however no changes in the dermis were noticed. It was apparent from the histology of the skin
sections treated with MKT formulations that there were no marked alterations to the normal tissue, which validates
the formulations biocompatibility. Upon application of EV and MKT formulation gel, the SC layer of rat skin
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Figure 8. Histological images of rat skin with and without treatment. Photographed sections of skin histology
treated with (A) control (B), ethanolic vesicles and (C) marketed formulations, respectively.
Figure 9. A review of the anti-acne potential of co-loaded azelaic acid–tea tree oil formulations with the
testosterone acne model. Presented here are photographs and histology of mouse skin representing (A & B) control;
(C & D) disease control (untreated), (E & F) ethanolic vesicle gel and (G & H) marketed gel.
became thinner, without an actual change in epidermis or dermis (Figure 8B & C). Encasement of the drug within
the biocompatible components viz., phospholipid and surfactant helps with safe delivery of drug. Additionally
appending carbopol R© 934 in the formulation, causes increased viscosity and development of three-dimensional
network structure minimizing the possibility of AzA directly contacting the skin, thus reducing any side effects [51].
Moreover the skin treated with EV hydrogel (Figure 8B) and MKT gel (Figure 8C) shows no sign of inflammation
cells attesting to better tolerability of the EV-based formulation. Therefore, the topical drugs delivered via EV
systems can be believed as safe.
Anti acne efficacy: testosterone induced acne model
Anti-acne potential of EV gel formulation was compared with MKT gel and untreated group; results are shown
in Figure 9. Visual evaluation of animal skin (Figure 9C) showed that TS application caused animals to develop
severe acne after 2 weeks and that the acne was alleviated in the animals after treatment with AzA formulations
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Table 5. Minimum inhibitory concentration values for azelaic acid, tea tree oil, azelaic acid and tea tree oil combination,
ethanolic vesicles and gel formulation against different test organisms.
Formulations MIC (mg/ml)
ATCC 29213 (S. aureus) MTCC 3382 (S. epidermidis) MTCC1951 (P. acnes)
AzA 0.78 0.78 3.12
EO 3.12 6.25 6.25
AzA with EO 0.78 0.78 1.56
EV 0.09 0.78 1.56
EV hydrogel 3.12 1.56 0.78
Erythromycin (+ve) 0.02 0.02 –
AzA: Azelaic acid; EO: Tea tree oil; EV: Ethanolic vesicle; MIC: Minimum inhibitory concentration.
Table 6. Stability studies of ethosomal suspension and ethanolic vesicle gel.
Time interval (days) Entrapment efficiency (%)
Ethosomal suspension Ethanolic vesicle gel
4 ± 2◦C 8 ± 2◦C Room temperature 4 ± 2◦C 8 ± 2◦C Room temperature
1 99.95% 99.95% 99.95% 98.77% 98.77% 98.77%
7 99.87% 99.75% 98.80% 98.62% 98.58% 98.45%
15 99.85% 98.90% 97.68% 98.68% 98.54% 98.40%
30 99.68% 98.66% 97.31% 98.58% 98.43% 98.35%
(Figure 9E & G). Macroscopic changes (visual) in skin and histopathology of animal clearly illustrated superiority
of AzA-EO co-loaded EV gel compared with MKT gel. In terms of mean percentage reductions in papule density,
following order was observed: MKT gel (63.12 ± 2.2%) <EV Hydrogel (78.80 ± 3.0%). In addition, the EV
gel treated group showed no signs of skin peeling and desquamation (indicative of toxicity), reflecting superior
tolerability and reduced toxicity compared with marketed MKT gel. In the histological evaluation, sebaceous
hyperplasia (i.e., increased number and size of sebaceous gland cells) and follicular hyperkeratosis in pilosbaceous
unit (Figure 9D) were observed, which are key indicators of acne development. In contrast, formulation-treated
animals showed a significant decrease of lesions, sebaceous gland hyperplasia, and seborrhea (Figure 9F) [41]. AzA’s
sustained release, its superior skin penetration, combined with its synergistic effect with EO’s, could explain the
superior therapeutic efficacy and tolerability of EV hydrogel in comparison to MKT formulation.
.
Stability studies
Ethosomal formulation showed 2% leakage of drug (from fluidized bilayer of the vesicle) at room temperature.
Moreover, hydrogel formulation, remained practically stable at all temperatures (Table 6).
Conclusion
EV and EV hydrogel formulations containing AzA and EO were successfully formulated and tested for efficacy
and safety in vitro, ex vivo, and in vivo. EV hydrogel formulations prevents direct contact of skin with the drug,
reduce the risk of adverse reactions, and have superior skin permeation and retention characteristics in comparison
to commercial formulations. However, EV hydrogel systems showed comparable antibacterial efficacy in vitro
with the commercial formulation, and showed good zone of inhibition and low MIC values against S. aureus,
S. epidermidis. In view of the dose-dependent side effects of AzA, the findings are of considerable importance.
Additional clinical studies will be needed to be performed to assess the potential of AzA and EO combination in
the form of EV hydrogel.
Future perspective
Ethosome hydrogel composite was better tolerated with no side effects. Thus, developed ethosome hydrogel
composite of AzA and EO, promises as an efficient and safe drug delivery system for the topical therapy of acne
vulgaris.
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Summary points
• The optimized AzA-EO ethosome was spherical, lamellar without any aggregation of uniform size (polydispersity
index = 0.821), nano-range (∼399 nm),% entrapment (∼99%) and positive zeta potential (1.62 mV) values.
• In vitro antibacterial efficacy in microbial strains such as Staphylococcus aureus, Staphylococcus epidermidis was
evaluated employing agar well plate diffusion and broth dilution assay. Ethosome exhibited appreciable zone of
inhibition (agar plate) and low minimum inhibitory concentration (MIC) (broth dilution) against S. aureus, S.
epidermidis vis-a-vis AzA.
• In testosterone induced acne model in rats, optimized ethosome exhibited better reduction in the papule density
(93.75 ± 1.64%) in comparison to AzidermTM (72.69 ± 4.67%).
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